AgomAb shares surge 47.53% after-hours after closing $200M IPO on Nasdaq.

AgomAb Therapeutics (AGMB) surged 47.53% in after-hours trading following the announcement of closing its $200 million initial public offering. The company issued 12.5 million American Depositary Shares at $16.00 per ADS, with gross proceeds before underwriting costs, and shares began trading on the Nasdaq Global Select Market on February 6, 2026. The IPO, led by J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen, provides AgomAb with capital to advance its pipeline of disease-modifying therapies targeting chronic fibrotic diseases. The significant after-hours rally reflects strong investor optimism about the successful fundraising and the company’s focus on high-unmet-need therapeutic areas, despite being a clinical-stage biopharma with no approved products.